Orchard Therapeutics press release
Orchard Therapeutics to Present at the Cowen and Company Annual Healthcare Conference
London, UK, March 06, 2018 -- Orchard Therapeutics, a clinical-stage biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced that Mark Rothera, president and chief executive officer, will present at the Cowen & Co. 38th Annual Healthcare Conference on Wednesday, March 14, 2018, at 11:30 a.m. ET in Boston.
About Orchard Therapeutics
Orchard Therapeutics is a privately held clinical-stage biotechnology company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard, based in the UK and US, has partnered with world leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital. Orchard’s growing pipeline of autologous ex vivo lentiviral gene therapy programs for rare immune deficiencies and metabolic disorders includes late clinical stage programs that have already demonstrated the transformative power of gene therapy on patients’ lives. In 2016 the company was named a Fierce 15 Company by Fierce Biotech and was awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM) to advance their autologous ex vivo lentiviral gene therapy in ADA-SCID. In 2017, Orchard raised $110 million in a Series B round of funding to further develop its pipeline in parallel with enhancing manufacturing capabilities.
+44 (0) 203 384 6700
Allison Blum, Ph.D.
LifeSci Public Relations
+1 516 655 0842